Blood Tests Join England GP Cancer Trial

General practitioners across England are set to administer blood tests designed to detect early signs of fourteen common cancers. The initiative marks the first time such a multi-cancer screening tool has been integrated into routine primary care to test whether it leads to earlier diagnoses and better survival rates.

The trial relies on technology developed by the University of Birmingham and its partners. These tests analyze blood samples using artificial intelligence and protein measurements to identify the presence of cancer and pinpoint its origin in the body. The specific cancers included in the study are prostate, ovarian, bowel, pancreatic, stomach, and liver, among others that are frequently diagnosed at advanced stages.

The decision to launch the trial follows a review of mortality data. Cancer death rates in Britain remain among the highest in the Organisation for Economic Co-operation and Development on a per capita basis. Researchers aim to address this gap by providing doctors with an additional diagnostic aid for patients presenting with abdominal symptoms such as persistent bloating or discomfort.

The study will involve at least 200 GP practices within the National Health Service. More than 20,000 patients aged forty-five and older will be eligible to participate. Participants will be those who visit their doctors with relevant symptoms and consent to the additional testing protocol.

The primary goal is to measure how well these tests support clinical judgment. The results will determine if the tools are effective enough to warrant a national rollout. The trial does not yet confirm that the tests will become standard practice, but it will provide the data needed to make that decision.